Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival.

No Thumbnail Available
Authors
Venkatadasari, Indrani
Issue Date
2024-04-22
Type
Letter/Correspondence
Language
Keywords
Haematology , Large B cell lymphoma , Letter
Research Projects
Organizational Units
Journal Issue
Alternative Title
Abstract
A reciprocal t(3;8) BCL6::MYC fusion is common in large B cell lymphoma (LBCL) with MYC and BCL6 disruption. These pseudo-double hit cases are not adverse, whereas t(3;8) negative MYC/BCL6 lymphoma has an inferior prognosis relative to other MYC-rearranged LBCL.
Description
Received 12th February 2024. Revised 10th April 2024. Accepted 11th April 2024. Published online 22nd April 2024.
Citation
Maybury BD, James LJ BSc (Hons), Phillips N, Venkatadasari I, Qureshi I, Riley JWE, Talbot G, Moosai S, Giles HV Dr, Chadderton N Mrs, Dowds J, Rakesh P, Crosland H, Haslam A, Lane S, Vega Gonzalez M, Davies D, Cherian G, Shenouda A, Kaudlay Sathyanarayana PK, Starczynski J, Rudzki Z, Chaganti S. Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival. Blood. 2024 Apr 22:blood.2024024048. doi: 10.1182/blood.2024024048. Epub ahead of print. PMID: 38648564.
Publisher
American Society of Hematology.
Rights
Journal
Blood
Volume
Issue
PubMed ID
ISSN
0006-4971
1528-0020
EISSN